<DOC>
	<DOC>NCT00278889</DOC>
	<brief_summary>The primary purpose of this study is to compare the efficacy of AZD2171 in combination with FOLFOX to the efficacy of bevacizumab in combination with FOLFOX, in the second-line treatment of patients with metastatic colorectal cancer</brief_summary>
	<brief_title>Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Clinical diagnosis of colon or rectal cancer, Received prior systemic therapy for cancer, Cancer must have progressed during or after first treatment Prior treatment with a VEGF inhibitor, Poorly controlled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Colorectal Cancer</keyword>
	<keyword>phase II</keyword>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>AZD2171</keyword>
	<keyword>RECENTIN</keyword>
</DOC>